Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Clinical trial NCT03872427 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03872427
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor Unresectable Malignant Solid Neoplasm

Start date: 2019-12-14
Primary completion: 2023-10-30
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.